Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm – not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closure
Malignant liver tumors affecting children and adolescents are rare. In order to adequately study liver tumors occurring in this patient population and establish a more uniform approach to therapy, the three primary liver tumor consortia, SIOPEL (mainly European), COG (mainly North American) and JCCG...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | EJC Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772610X25000236 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849422513345396736 |
|---|---|
| author | Irene Schmid Allison F. O’Neill Kenichiro Watanabe Isabelle Aerts Sophie Branchereau Penelope R. Brock Madhumita Dandapani Brice Fresneau Jim Geller Tomoro Hishiki Danielle Ingham Kathelijne Kraal Milind Ronghe Greg Tiao Angela Trobaugh-Lotrario Arun Rangaswami Michael J. Sullivan Jozsef Zsiros Eiso Hiyama Marcio Malogolowkin Marc Ansari |
| author_facet | Irene Schmid Allison F. O’Neill Kenichiro Watanabe Isabelle Aerts Sophie Branchereau Penelope R. Brock Madhumita Dandapani Brice Fresneau Jim Geller Tomoro Hishiki Danielle Ingham Kathelijne Kraal Milind Ronghe Greg Tiao Angela Trobaugh-Lotrario Arun Rangaswami Michael J. Sullivan Jozsef Zsiros Eiso Hiyama Marcio Malogolowkin Marc Ansari |
| author_sort | Irene Schmid |
| collection | DOAJ |
| description | Malignant liver tumors affecting children and adolescents are rare. In order to adequately study liver tumors occurring in this patient population and establish a more uniform approach to therapy, the three primary liver tumor consortia, SIOPEL (mainly European), COG (mainly North American) and JCCG (Japan), in concert, designed an international prospective clinical trial [PHITT (Paediatric Hepatic International Tumour Trial)/COGAHEP1531/JPLT4 – to be referred to as PHITT from this point forth] for the study of hepatoblastoma and hepatocellular carcinoma in children and adolescents. Recruitment to PHITT has recently concluded. The major results from this trial will be published in the next 2–3 years, therefore in the interim, we sought to provide a consensus statement on evidence-based chemotherapy guidance for hepatoblastoma and hepatocellular carcinoma of all stages. |
| format | Article |
| id | doaj-art-9b3f06cc83fa41528a530fa49f9868c7 |
| institution | Kabale University |
| issn | 2772-610X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EJC Paediatric Oncology |
| spelling | doaj-art-9b3f06cc83fa41528a530fa49f9868c72025-08-20T03:31:05ZengElsevierEJC Paediatric Oncology2772-610X2025-06-01510023510.1016/j.ejcped.2025.100235Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm – not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closureIrene Schmid0Allison F. O’Neill1Kenichiro Watanabe2Isabelle Aerts3Sophie Branchereau4Penelope R. Brock5Madhumita Dandapani6Brice Fresneau7Jim Geller8Tomoro Hishiki9Danielle Ingham10Kathelijne Kraal11Milind Ronghe12Greg Tiao13Angela Trobaugh-Lotrario14Arun Rangaswami15Michael J. Sullivan16Jozsef Zsiros17Eiso Hiyama18Marcio Malogolowkin19Marc Ansari20Department of Pediatric Hematology and Oncology, Dr. von Hauner Children`s Hospital, University of Munich, LMU Munich, Germany; Correspondence to: Dr. von Hauner Children`s Hospital, Department of Pediatric Hematology and Oncology, University of Munich, LMU Munich, Lindwurmstr, Munich, Germany.Department of Pediatric Oncology, Dana-Farber and Boston Children’s Cancer and Blood Disorder Center, and Harvard Medical School, Boston, MA, USADepartment of Hematology and Oncology, Shizuoka Children's Hospital, Shizuoka, JapanInstitut Curie, PSL Research University, Oncology Center SIREDO, Paris, FranceBicetre Hospital APHP, Paris Saclay University, FranceOncology Department, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United KingdomDepartment of Paediatric Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UKDepartment of Children and Adolescent Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, FranceDivision of Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USAPediatric Surgery, Chiba University Hospital, Chiba, JapanDepartment of Paediatric Oncology & Haematology, Leeds Children's Hospital, Leeds, United KingdomPrincess Maxima Center for Pediatric Oncology, Utrecht, the NetherlandsDepartment of Paediatric Oncology, Royal Hospital for Children, Glasgow, United KingdomPediatric Surgery, University of Cincinnati, Cincinnati, USAProvidence Sacred Heart Children's Hospital, Spokane, WA, USADivision of Pediatric Hematology and Oncology, University of California San Francisco, San Francisco, California, USAThe Royal Children's Hospital, Melbourne, AustraliaPrincess Maxima Center for Pediatric Oncology, Utrecht, the NetherlandsDepartment of Pediatric Surgery, Hiroshima University Hospital, Hiroshima, JapanDivision of Pediatric Hematology-Oncology, Department of Pediatrics, US Davis Comprehensive Cancer Center, Sacramento, USACansearch Research platform for Pediatric =ncology and Hematology, Faculty of Medicine, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Switzerland; Division of Pediatric Oncology and Hematology, Department of Women, Child and Adolescent, University Geneva Hospitals, Geneva, SwitzerlandMalignant liver tumors affecting children and adolescents are rare. In order to adequately study liver tumors occurring in this patient population and establish a more uniform approach to therapy, the three primary liver tumor consortia, SIOPEL (mainly European), COG (mainly North American) and JCCG (Japan), in concert, designed an international prospective clinical trial [PHITT (Paediatric Hepatic International Tumour Trial)/COGAHEP1531/JPLT4 – to be referred to as PHITT from this point forth] for the study of hepatoblastoma and hepatocellular carcinoma in children and adolescents. Recruitment to PHITT has recently concluded. The major results from this trial will be published in the next 2–3 years, therefore in the interim, we sought to provide a consensus statement on evidence-based chemotherapy guidance for hepatoblastoma and hepatocellular carcinoma of all stages.http://www.sciencedirect.com/science/article/pii/S2772610X25000236HepatoblastomaHepatocellular CarcinomaHepatocellular Neoplasm – Not Otherwise SpecifiedInterim guidanceChildrenChemotherapy |
| spellingShingle | Irene Schmid Allison F. O’Neill Kenichiro Watanabe Isabelle Aerts Sophie Branchereau Penelope R. Brock Madhumita Dandapani Brice Fresneau Jim Geller Tomoro Hishiki Danielle Ingham Kathelijne Kraal Milind Ronghe Greg Tiao Angela Trobaugh-Lotrario Arun Rangaswami Michael J. Sullivan Jozsef Zsiros Eiso Hiyama Marcio Malogolowkin Marc Ansari Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm – not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closure EJC Paediatric Oncology Hepatoblastoma Hepatocellular Carcinoma Hepatocellular Neoplasm – Not Otherwise Specified Interim guidance Children Chemotherapy |
| title | Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm – not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closure |
| title_full | Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm – not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closure |
| title_fullStr | Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm – not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closure |
| title_full_unstemmed | Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm – not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closure |
| title_short | Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm – not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closure |
| title_sort | global consensus from the phitt consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma hepatocellular neoplasm not otherwise specified hcn nos hepatocellular carcinoma and fibrolamellar carcinoma after trial closure |
| topic | Hepatoblastoma Hepatocellular Carcinoma Hepatocellular Neoplasm – Not Otherwise Specified Interim guidance Children Chemotherapy |
| url | http://www.sciencedirect.com/science/article/pii/S2772610X25000236 |
| work_keys_str_mv | AT ireneschmid globalconsensusfromthephittconsortiumsurroundinganinterimchemotherapyguidanceforthetreatmentofchildrenwithhepatoblastomahepatocellularneoplasmnototherwisespecifiedhcnnoshepatocellularcarcinomaandfibrolamellarcarcinomaaftertrialclosure AT allisonfoneill globalconsensusfromthephittconsortiumsurroundinganinterimchemotherapyguidanceforthetreatmentofchildrenwithhepatoblastomahepatocellularneoplasmnototherwisespecifiedhcnnoshepatocellularcarcinomaandfibrolamellarcarcinomaaftertrialclosure AT kenichirowatanabe globalconsensusfromthephittconsortiumsurroundinganinterimchemotherapyguidanceforthetreatmentofchildrenwithhepatoblastomahepatocellularneoplasmnototherwisespecifiedhcnnoshepatocellularcarcinomaandfibrolamellarcarcinomaaftertrialclosure AT isabelleaerts globalconsensusfromthephittconsortiumsurroundinganinterimchemotherapyguidanceforthetreatmentofchildrenwithhepatoblastomahepatocellularneoplasmnototherwisespecifiedhcnnoshepatocellularcarcinomaandfibrolamellarcarcinomaaftertrialclosure AT sophiebranchereau globalconsensusfromthephittconsortiumsurroundinganinterimchemotherapyguidanceforthetreatmentofchildrenwithhepatoblastomahepatocellularneoplasmnototherwisespecifiedhcnnoshepatocellularcarcinomaandfibrolamellarcarcinomaaftertrialclosure AT peneloperbrock globalconsensusfromthephittconsortiumsurroundinganinterimchemotherapyguidanceforthetreatmentofchildrenwithhepatoblastomahepatocellularneoplasmnototherwisespecifiedhcnnoshepatocellularcarcinomaandfibrolamellarcarcinomaaftertrialclosure AT madhumitadandapani globalconsensusfromthephittconsortiumsurroundinganinterimchemotherapyguidanceforthetreatmentofchildrenwithhepatoblastomahepatocellularneoplasmnototherwisespecifiedhcnnoshepatocellularcarcinomaandfibrolamellarcarcinomaaftertrialclosure AT bricefresneau globalconsensusfromthephittconsortiumsurroundinganinterimchemotherapyguidanceforthetreatmentofchildrenwithhepatoblastomahepatocellularneoplasmnototherwisespecifiedhcnnoshepatocellularcarcinomaandfibrolamellarcarcinomaaftertrialclosure AT jimgeller globalconsensusfromthephittconsortiumsurroundinganinterimchemotherapyguidanceforthetreatmentofchildrenwithhepatoblastomahepatocellularneoplasmnototherwisespecifiedhcnnoshepatocellularcarcinomaandfibrolamellarcarcinomaaftertrialclosure AT tomorohishiki globalconsensusfromthephittconsortiumsurroundinganinterimchemotherapyguidanceforthetreatmentofchildrenwithhepatoblastomahepatocellularneoplasmnototherwisespecifiedhcnnoshepatocellularcarcinomaandfibrolamellarcarcinomaaftertrialclosure AT danielleingham globalconsensusfromthephittconsortiumsurroundinganinterimchemotherapyguidanceforthetreatmentofchildrenwithhepatoblastomahepatocellularneoplasmnototherwisespecifiedhcnnoshepatocellularcarcinomaandfibrolamellarcarcinomaaftertrialclosure AT kathelijnekraal globalconsensusfromthephittconsortiumsurroundinganinterimchemotherapyguidanceforthetreatmentofchildrenwithhepatoblastomahepatocellularneoplasmnototherwisespecifiedhcnnoshepatocellularcarcinomaandfibrolamellarcarcinomaaftertrialclosure AT milindronghe globalconsensusfromthephittconsortiumsurroundinganinterimchemotherapyguidanceforthetreatmentofchildrenwithhepatoblastomahepatocellularneoplasmnototherwisespecifiedhcnnoshepatocellularcarcinomaandfibrolamellarcarcinomaaftertrialclosure AT gregtiao globalconsensusfromthephittconsortiumsurroundinganinterimchemotherapyguidanceforthetreatmentofchildrenwithhepatoblastomahepatocellularneoplasmnototherwisespecifiedhcnnoshepatocellularcarcinomaandfibrolamellarcarcinomaaftertrialclosure AT angelatrobaughlotrario globalconsensusfromthephittconsortiumsurroundinganinterimchemotherapyguidanceforthetreatmentofchildrenwithhepatoblastomahepatocellularneoplasmnototherwisespecifiedhcnnoshepatocellularcarcinomaandfibrolamellarcarcinomaaftertrialclosure AT arunrangaswami globalconsensusfromthephittconsortiumsurroundinganinterimchemotherapyguidanceforthetreatmentofchildrenwithhepatoblastomahepatocellularneoplasmnototherwisespecifiedhcnnoshepatocellularcarcinomaandfibrolamellarcarcinomaaftertrialclosure AT michaeljsullivan globalconsensusfromthephittconsortiumsurroundinganinterimchemotherapyguidanceforthetreatmentofchildrenwithhepatoblastomahepatocellularneoplasmnototherwisespecifiedhcnnoshepatocellularcarcinomaandfibrolamellarcarcinomaaftertrialclosure AT jozsefzsiros globalconsensusfromthephittconsortiumsurroundinganinterimchemotherapyguidanceforthetreatmentofchildrenwithhepatoblastomahepatocellularneoplasmnototherwisespecifiedhcnnoshepatocellularcarcinomaandfibrolamellarcarcinomaaftertrialclosure AT eisohiyama globalconsensusfromthephittconsortiumsurroundinganinterimchemotherapyguidanceforthetreatmentofchildrenwithhepatoblastomahepatocellularneoplasmnototherwisespecifiedhcnnoshepatocellularcarcinomaandfibrolamellarcarcinomaaftertrialclosure AT marciomalogolowkin globalconsensusfromthephittconsortiumsurroundinganinterimchemotherapyguidanceforthetreatmentofchildrenwithhepatoblastomahepatocellularneoplasmnototherwisespecifiedhcnnoshepatocellularcarcinomaandfibrolamellarcarcinomaaftertrialclosure AT marcansari globalconsensusfromthephittconsortiumsurroundinganinterimchemotherapyguidanceforthetreatmentofchildrenwithhepatoblastomahepatocellularneoplasmnototherwisespecifiedhcnnoshepatocellularcarcinomaandfibrolamellarcarcinomaaftertrialclosure |